AbCellera Biologics Operating Income

The latest operating income for ABCL is $-230M as of June 2026. That compares with $-320M in the prior-year period — up 29.9% year over year. Investors often review this figure alongside AbCellera Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABCL's operating income moved from $-320M to $-230M — a 29.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AbCellera Biologics's operating scale or balance-sheet position.

A operating income figure of $-230M for ABCL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ABCL's operating income ($-230M), review year-over-year change from $-320M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.